FGEN vs. KNTE, MCRB, INO, MNMD, OCUP, CDMO, GRCL, CRMD, TRVI, and ADVM
Should you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Kinnate Biopharma (KNTE), Seres Therapeutics (MCRB), Inovio Pharmaceuticals (INO), Mind Medicine (MindMed) (MNMD), Ocuphire Pharma (OCUP), Avid Bioservices (CDMO), Gracell Biotechnologies (GRCL), CorMedix (CRMD), Trevi Therapeutics (TRVI), and Adverum Biotechnologies (ADVM). These companies are all part of the "medical" sector.
Kinnate Biopharma (NASDAQ:KNTE) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.
78.3% of FibroGen shares are owned by institutional investors. 41.7% of Kinnate Biopharma shares are owned by company insiders. Comparatively, 2.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Kinnate Biopharma has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
Kinnate Biopharma has a net margin of 0.00% compared to Kinnate Biopharma's net margin of -192.37%. Kinnate Biopharma's return on equity of 0.00% beat FibroGen's return on equity.
Kinnate Biopharma presently has a consensus price target of $11.72, suggesting a potential upside of 359.53%. FibroGen has a consensus price target of $17.00, suggesting a potential upside of 683.41%. Given Kinnate Biopharma's higher probable upside, analysts plainly believe FibroGen is more favorable than Kinnate Biopharma.
FibroGen received 329 more outperform votes than Kinnate Biopharma when rated by MarketBeat users. Likewise, 62.36% of users gave FibroGen an outperform vote while only 40.00% of users gave Kinnate Biopharma an outperform vote.
In the previous week, Kinnate Biopharma had 4 more articles in the media than FibroGen. MarketBeat recorded 4 mentions for Kinnate Biopharma and 0 mentions for FibroGen. Kinnate Biopharma's average media sentiment score of 1.28 beat FibroGen's score of 0.85 indicating that FibroGen is being referred to more favorably in the news media.
Kinnate Biopharma has higher earnings, but lower revenue than FibroGen. Kinnate Biopharma is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks.
Summary
FibroGen beats Kinnate Biopharma on 9 of the 17 factors compared between the two stocks.
Get FibroGen News Delivered to You Automatically
Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
FibroGen Competitors List
Related Companies and Tools